Controlled Substance Monitoring

Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.

Join us for the APA Annual Meeting 2023, the premier event for psychiatrists and mental health professionals. This year's meeting will be held May 20–24 in San Francisco and will feature an exciting program of educational sessions, expert speakers, and networking opportunities.

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.

Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new comprehensive Controlled Substance Monitoring Panel, developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic Laboratories, offers in-depth analysis on more than 70 different prescription medications and illicit substances to provide clinicians with details and interpretations on patients’ controlled substance use lacking in other laboratory assays.

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.